Systematic overview of cost-utility assessments in oncology

Journal of Clinical Oncology

Volumn 18, Issue 18, 2000, Pages 3302-3317

  Earle, C C ^a   Chapman, R H ^a   Baker, C S ^a   Bell, C M ^a   Stone, P W ^a   Sandberg, E A ^a   Neumann, P J ^a  

^a HARVARD CENTER FOR RISK ANALYSIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER SURVIVAL; CANCER THERAPY; CLINICAL PRACTICE; COST UTILITY ANALYSIS; HUMAN; MEDICAL LITERATURE; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0034666171     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.18.3302     Document Type: Article

References (73)

1. Economic analyses in health care: An introduction to the methodology with an emphasis on radiation therapy
2. European School of Oncology advisory report to the Commission of the European Communities for the 'Europe Against Cancer Programme' cost-effectiveness in cancer care
3. Recommendations for reporting cost-effectiveness analyses
4. Recommendations of the panel on cost-effectiveness in health and medicine
5. The quality of reporting in published cost-utility analyses, 1976-1977
6. Five-hundred life-saving interventions and their cost-effectiveness
7. Developing the health care market
8. Cost-effectiveness of low-dose zidovudine therapy for asymptomatic patients with human deficiency virus (HIV) infection
9. Efficacy and cost-effectiveness of cancer treatment: Rational allocation of resources based on decision analysis
10. Ways to reduce the cost of oncology care without compromising the quality
11. A comprehensive league table of cost-utility ratios and a sub-table of 'panel-worthy' studies
12. Cost-utility analyses of clinical prevention services: A summary of a league table
13. Measuring costs in cost-utility analyses: Variation in the literature
14. An off-the-shelf-help list: A comprehensive catalog of preference weights from published cost-utility analyses
15. A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer
16. Multiattribute utility function for a comprehensive health status classification system
17. Evaluation of conflict of interest in economic analyses of new drugs used in oncology
18. Are Pharmaceuticals cost-effective? A review of the evidence
19. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer
20. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017
21. Breast cancer screening and cost-effectiveness; policy alternatives, quality of life considerations and the possible impact of uncertain factors
22. Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer: Estimates using decision analysis while awaiting clinical trial results
23. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer: Docetaxel versus paclitaxel versus vinorelbine
24. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer: A decision-analysis model
25. The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women
26. Lumpectomy or mastectomy? Is breast conserving surgery too expensive?
27. The costs and benefits of bone marrow transplantation
28. Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia
29. Treatment costs in Hodgkin's disease: A cost-utility analysis
30. Cost-effectiveness of cancer chemotherapy: An economic evaluation of a randomized trial in small-cell lung cancer
31. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia
32. Cost-effective models for flutamide for prostate carcinoma patients. Are they helpful to policy makers?
33. Screening for prostate cancer: A decision analytic view
34. Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer
35. Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha-2B in newly diagnosed multiple myeloma - Results from a randomised controlled trial
36. The effect of a patient's risk-taking attitude on the cost effectiveness of testing strategies in the evaluation of pulmonary lesions
37. Economic analysis of adjuvant interferon alfa-2B in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684
38. Cost-effectiveness of endorectal magnetic resonance imaging for the staging of prostate cancer
39. Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL)
40. A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma
41. Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma: A cost-effectiveness analysis
42. Utility and cost of carcinoembryonic antigen monitoring in colon cancer follow-up evaluation: A Markov analysis
43. The cost-effectiveness of cervical cancer screening for low-income elderly women
44. Cost-effectiveness of interferon alfa in chronic myelogenous leukemia
45. The prostate-decreasing cost-effectiveness of biopsy with advancing age
46. Immediate biopsy versus observation for abnormal findings on mammograms: An analysis of potential outcomes and costs
47. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer
48. A cost utility analysis of mammography screening in Australia
49. In search of the best upper age limit for breast cancer screening
50. A cost-effectiveness approach to the Norwegian follow-up programme in colorectal cancer
51. A model of chemotherapy in node-negative breast cancer
52. Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes
53. Assessing the cost effectiveness of adjuvant therapies in early breast cancer using a decision analysis model
54. Cost-effectiveness of head CT in patients with lung cancer without clinical evidence of metastases
55. Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting
56. Life-long screening of patients with intermediate-thickness cutaneous melanoma for asymptomatic pulmonary recurrences: A cost-effectiveness analysis
57. Detection of recurrence after surgery for colorectal cancer
58. Utilities and quality-adjusted life years
59. Multi-attribute preference functions: Health Utilities Index
60. A general health policy model: Update and applications
61. EuroQol: A new facility for the measurement of health related quality of life
62. Attitudes to chemotherapy: Comparing views of patients with cancer with those of doctors, nurses, and general public
63. Some guidelines on the use of cost effectiveness league tables
64. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations
65. Cost-effectiveness league tables: More harm than good?
66. Comparing cost-effectiveness across countries: The model of acid-related disease
67. Issues in the cross-national assessment of health technology
68. Economic value of gemcitabine in non-small cell lung cancer